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ABSTRACT 
The standard-of-care therapeutics for the treatment of ocular neovascular diseases like wet 
age-related macular degeneration (AMD) are biologics targeting vascular endothelial growth 
factor signaling. There are currently no FDA approved small molecules for treating these 
blinding eye diseases. Therefore, therapeutic agents with novel mechanisms are critical to 
complement or combine with existing approaches. Here, we identified soluble epoxide 
hydrolase (sEH), a key enzyme for epoxy fatty acid metabolism, as a target of an 
antiangiogenic homoisoflavonoid, SH-11037. SH-11037 inhibits sEH in vitro and in vivo and 
docks to the substrate binding cleft in the sEH hydrolase domain. sEH levels and activity are 
upregulated in the eyes of a choroidal neovascularization (CNV) mouse model. sEH is 
overexpressed in human wet AMD eyes, suggesting that sEH is relevant to neovascularization. 
Known sEH inhibitors delivered intraocularly suppressed CNV. Thus, by dissecting a bioactive 
compound’s mechanism, we identified a new chemotype for sEH inhibition and characterized 
sEH as a target for blocking the CNV that underlies wet AMD. 
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Ocular neovascularization is the underlying cause of blindness in diseases such as 
retinopathy of prematurity (ROP), proliferative diabetic retinopathy (PDR), and wet age-related 
macular degeneration (AMD), which cause blindness in infants, adults of working age and the 
elderly, respectively.1 Current FDA approved treatments for wet AMD focus on inhibiting the 
vascular endothelial growth factor (VEGF) signaling pathway using biologics such as 
ranibizumab and aflibercept.2 Despite the success of these therapeutic agents, their 
association with ocular and systemic side effects due to inhibition of such a major angiogenic 
pathway, and the presence of resistant and refractory patient populations complicate their 
use.3, 4 Thus, discovery of new therapeutic targets is crucial. Alternative angiogenic targets 
could lead to new therapeutics to complement and combine with the existing medications. 
We previously characterized a novel antiangiogenic homoisoflavonoid derivative, SH-
11037 (1; Figure 1a), in vitro5 and in vivo.6 SH-11037 had potent antiangiogenic activities in the 
laser-induced choroidal neovascularization (L-CNV) mouse model, a widely-used system that 
recapitulates some of the features of wet AMD.7 Therefore, characterization of its mechanism 
of action is important. We used an unbiased forward chemical genetics approach to identify 
SH-11037 protein targets that might be potentially druggable angiogenic mediators. We first 
synthesized two photoaffinity reagents 2 and 3 that retained antiangiogenic activity, and a 
control compound 4 (Figure 1a).8 The ester group in 2 (shared with SH-11037) was replaced 
by an amide in 3 for increased stability. The SH-11037-based affinity reagents 2 and 3 were 
immobilized and used to pull down protein binding partners from a porcine brain lysate. Affinity 
reagent 3 but not the negative control reagent 4 pulled down a specific protein target, which 
was identified as soluble epoxide hydrolase (Figure 1b; Supplementary Figure 1). Immunoblot 
confirmed the identity of the pulled down protein (Figure 1c).  
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Docking of SH-11037 to sEH (Figure 1d) shows a binding mode in which the compound 
occupies nearly the entire active site of the enzyme.  The homoisoflavonoid group of SH-
11037 occupies the site where the catalytic Asp335 and Tyr466 residues of sEH are located.9  
Both aromatic rings of the homoisoflavonoid group are involved in π-π interactions with sEH 
residues that include His524 and Trp336 (Figure 1e). The benzyl substituent of the peptidic 
moiety of SH-11037 is ensconced into a hydrophobic cavity created by Trp473, Met503, 
Ile363, and Phe362.  The substituent is located near an opening through which the linker of 2 
or 3 is attached to SH-11037.  Extensive molecular dynamics simulations reveal that this 
moiety is flexible as illustrated by root-mean-square deviations for SH-11037 that range from 
1.2 to 2.8 Å (Supplementary Figure 2). Animation of the molecular dynamics simulations 
(Supplementary movie) reveals that the benzene ring periodically adopts a conformation 
whereby the para position of the ring is exposed to solvent. This is likely the conformation that 
is adopted by the benzyl group in compounds 2 and 3.   
Soluble epoxide hydrolase (sEH, encoded by EPHX2) is a 62 kDa bifunctional enzyme 
that has N-terminal lipid phosphatase (EC 3.1.3.76) and C-terminal epoxide hydrolase (EC 
3.3.2.10) activities.10 While the physiological role of the lipid phosphatase activity of sEH is not 
fully understood, its epoxide hydrolase activity has been extensively studied due to its role in 
the metabolism of arachidonic acids’ epoxide derivatives, epoxyeicosatrienoic acids (EETs).11 
EETs have proangiogenic effects resulting in accelerating tumor growth,12 and play a role in 
hypertension, pain and inflammation. Therefore, sEH inhibitors have been in clinical trials for 
treating related conditions.13, 14 But additionally, sEH is involved in the metabolism of the 
epoxides of ω-3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), 
which are more abundant in the eye than EETs.15 
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Following the identification of sEH as a binding target of SH-11037, we tested whether 
the compound interferes with the epoxide hydrolase activity of sEH in vitro, compared to 
known sEH inhibitors. Trans-4-(4-[3-adamantan-1-yl-ureido]-cyclohexyloxy)-benzoic acid (t-
AUCB (5); Figure 2a) is a specific inhibitor of the epoxide hydrolase activity of sEH, widely 
used in preclinical studies.16 Meanwhile, 7-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl) 
benzo[d]isoxazol-3-amine (7), is a structurally distinct benzisoxazole inhibitor with excellent 
potency and pharmacokinetic properties.17 Interestingly, SH-11037 inhibited sEH enzymatic 
activity in vitro in a concentration-dependent manner (Figure 2a), although not as potently as t-
AUCB or 7. To test whether these effects are specific to SH-11037, we used as a negative 
control SH-11098 (6), which is a homoisoflavonoid that was found to be inactive in 
angiogenesis assays in vitro.5 This related compound had minimal inhibitory activity, 
suggesting that structural features of SH-11037 specifically interact with sEH.  
Enzyme kinetics analysis showed that increasing concentrations of SH-11037 
decreased Vmax and increased KM, revealing that SH-11037 is a mixed-type inhibitor of sEH 
(Figure 2b, c, d), with Ki = 1.73 ± 0.45 µM. Compound 7 is also a mixed-type inhibitor 
(Supplementary Figure 3).  Furthermore, secondary plots of KMapp/Vmaxapp and 1/Vmaxapp vs. 
[SH-11037] and [7] fit the curves expected for mixed-type inhibition (Supplementary Figure 4). 
The catalytic mechanism of sEH proceeds as a nucleophilic attack onto the epoxide substrate 
by an Asp residue, which results in a tetrahedral intermediate, requiring activated water to 
release the diol and regenerate free enzyme.9 Given that sEH has two substrates (in our 
assay, the fluorogenic substrate 3-phenyl-cyano(6-methoxy-2-naphthalenyl)methyl ester-2-
oxiraneacetic acid [PHOME] and water), and involves a covalent intermediate, it is possible 
that SH-11037 may bind and stabilize an enzyme species late in the catalytic cycle that is still 
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in conformational equilibrium with the free enzyme. SH-11037 binding in the active site of such 
an enzyme species may not compete with the substrates. Taken together, these findings 
indicate that SH-11037 represents a novel, distinct chemotype from known sEH inhibitors,18 
although interestingly, some other flavonoid natural products have previously been identified 
as mixed-type sEH inhibitors.19 
After establishing SH-11037’s in vitro inhibition of sEH activity, it was crucial to assess 
whether the previously documented antiangiogenic effects of SH-110376 were mediated 
through the inhibition of sEH in the L-CNV model. Therefore, we analyzed the lipid profiles of 
the retina/choroid layers from mice, at an acute timepoint three days after CNV induction and 
intravitreal injections of 10 µM SH-11037 or t-AUCB. Since DHA is the most abundant 
bioactive lipid in the eye,15 DHA epoxy and dihydroxy metabolite levels were evaluated to 
investigate sEH activity in vivo. Interestingly, 19,20-epoxydocosapentaenoic acid (EDP) and its 
dihydroxy metabolite, 19,20-dihydroxydocosapentaenoic acid (DHDP) were the DHA 
metabolites most affected by sEH inhibition (Figure 2e). The ratio of 19,20-EDP to 19,20-
DHDP decreased after induction of neovascularization, indicative of enhanced sEH activity 
under these conditions. However, this ratio was partially normalized after SH-11037 or t-AUCB 
treatment compared to the vehicle treated controls, indicating sEH inhibition in vivo (Figure 2f). 
Despite being less potent than t-AUCB in vitro (Figure 2a), SH-11037 performed comparably in 
vivo (Figure 2f), perhaps indicative of better ocular bioavailability than the existing inhibitor. To 
our knowledge, this is the first evidence that local sEH chemical inhibition can alter the lipid 
balance in the eye. 
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Given the significantly suppressed ratio of 19,20 EDP/DHDP after induction of CNV 
compared to the untreated control, suggestive of increased sEH activity, we investigated 
whether there are differences in sEH expression during neovascularization. Intriguingly, L-CNV 
treated mice demonstrated substantial upregulation of sEH in photoreceptor layers, both within 
and surrounding the neovascular lesion, compared to untreated eyes (Figure 3a). This 
upregulation of sEH in L-CNV was further confirmed in immunoblots of retina and choroid 
layers of laser-treated mouse eyes relative to untreated controls (Figure 3b). Co-
immunostaining revealed co-localization of upregulated sEH levels with rod photoreceptors in 
the eyes of L-CNV mice compared to controls (Figure 3c, Supplementary Figure 5), but no 
overlap with markers of other retinal cell types, including retinal ganglion cells, horizontal cells, 
Müller glia, and cone photoreceptors (Supplementary Figures 5, 6, 7, 8). This increase in 
immunostaining corresponded to an increase in sEH activity in L-CNV eye lysates, which could 
be normalized by SH-11037 or compound 7 treatment (Figure 3d). Surprisingly, postmortem 
human wet AMD patients’ eyes also revealed changed sEH expression in the central retina 
compared to age-matched controls: an increase in the staining pattern of sEH in the inner 
retina seen in age-matched control retina, and aberrant expression in some photoreceptors 
(Figure 3e; Supplementary Figure 9). Together, these data strongly suggest a role for retinal 
sEH in the CNV process both in mice and humans.  
sEH is widely expressed in various tissues, with the highest levels of expression seen in 
liver, kidney, and brain in neuronal cell bodies and astrocytes.20, 21 In mouse eye development 
it is expressed in Müller glial cells,22 and in oxygen-induced retinopathy in neonatal mice, 
expression is seen in retinal ganglion cells, neovessels, and inner nuclear layer neurons.23 Our 
data suggest a differential expression pattern in the adult mouse eye, especially under CNV 
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stress. Aged human eyes, in turn, have another pattern of expression, but this could also be a 
species difference: the rod-specific sEH expression seen in response to CNV in the rod-
dominant, nocturnal murine eye might be expected to be shared by other cell types, as we 
observed, in the cone-dominant human macula.  
Several studies have demonstrated potent antiangiogenic effects of DHA and its 
epoxides in the eye after genetic manipulation and/or dietary or i.p. administration,22, 24–28 
although a few studies showed proangiogenic effects.23, 29, 30 To date however, inhibition of 
sEH using small molecules has only been tested in L-CNV using systemic administration 
through i.p. injections28, 29, and showed antiangiogenic effects only when diet was 
supplemented with ω-3 fatty acids or their epoxides.28 Given that the arachidonic acid pathway 
leading to EET formation is dominant systemically,31 unlike in the eye, the effects of EDP 
buildup after systemic sEH inhibition might be partially offset by the concomitant proangiogenic 
EET buildup. Thus, local sEH inhibition is appealing. 
To address this, we sought to test sEH inhibitors locally, using intravitreal injections, to 
minimize any systemic side effects and focus on understanding the effects of sEH in the eye 
specifically. We previously showed that SH-11037 was effective at doses ≥ 1 µM in this 
context.6 Here, to validate sEH as a key target, we assessed the antiangiogenic effect of two 
chemically distinct small molecule inhibitors of sEH, t-AUCB (5) and compound 7, in L-CNV 
(Figure 4). A single injection of either t-AUCB or compound 7 dose-dependently suppressed 
CNV lesion vascular volume compared to vehicle (Figure 4a-c), and comparable to the 
standard of care-equivalent anti-VEGF164 antibody, suggesting indeed that sEH inhibition 
directly in the eye does not require ω-3 supplementation for antiangiogenic efficacy. 
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Additionally, in order to confirm our observations in a different model system, we tested t-
AUCB and compound 7 in the choroidal sprouting assay, as an ex vivo model of CNV.6 
Interestingly, both t-AUCB and compound 7 suppressed the ability of choroidal tissues to form 
sprouts (Figure 4d-e).  
The effect of ω-3 polyunsaturated fatty acids (PUFA) levels on choroidal 
neovascularization has been previously reported in vivo in the L-CNV model24, 25 and in wet 
AMD patients.32 Interestingly, in the retina of sEH knockout mice, pronounced changes in the 
levels of 19,20-DHDP, but not the epoxy metabolites of DHA, compared to wild-type control 
mice were observed.22 Moreover, 19,20-DHDP could rescue the suppressed developmental 
retinal angiogenesis phenotype observed with these mice,22 and as noted i.p. injections of 
19,20-EDP suppressed CNV lesion volume in the L-CNV mouse model.25, 28 While the 
explanation for the absence of changes in other EDPs after sEH inhibition or knockout is not 
clear, it is possible that the DHA epoxy (19,20-EDP) and diol (19,20-DHDP) metabolites and 
the activity of sEH are the major factors underlying the observed changes in retinal and 
choroidal angiogenesis rather than DHA levels themselves. Despite the role of DHA in the eye, 
the variability in the circulating levels of DHA among individuals suggests that dietary intake of 
ω-3 PUFA would not be sufficient alone for the prevention or treatment of wet AMD.32 
Therefore, local small molecule inhibition of sEH is an appealing therapeutic approach of 
significant interest for wet AMD patients to augment DHA epoxy metabolite levels with or 
without dietary supplementation of ω-3 PUFA (Figure 4f).  
In conclusion, our findings reveal not only the target of an antiangiogenic molecule and 
a novel chemotype for sEH inhibition, but also a central role for local sEH in ocular 
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 10 
neovascularization. Developing novel, ocular specific sEH-targeted therapies is a possible 
approach to complement or combine with the existing anti-VEGF medications to overcome 
their limitations and tackle multiple angiogenesis signaling pathways for improved treatment of 
wet AMD; we already showed that SH-11037 can synergize with an anti-VEGF antibody in L-
CNV.6 Additionally, sEH and its inhibition using small molecules such as SH-11037 could be 
further investigated in other ocular neovascular diseases including PDR and ROP. 
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FIGURES  
Figure 1. Soluble epoxide hydrolase (sEH) is a target of antiangiogenic homoisoflavonoid SH-
11037. a) Structures of SH-11037 (1), ester affinity reagent (2), amide affinity reagent (3), and 
negative control reagent (4). BP, benzophenone moiety. b) Proteins pulled down with indicated 
reagents were separated by SDS-PAGE and silver stained, then identified by mass 
spectrometry. A unique band was present in pulldown with 3 but not 4, red box; asterisks 
represent non-specific bands. c) Immunoblot of pulled down protein using antibody against 
sEH. Silver-stained gel and immunoblot are representatives from at least two independent 
experiments. d) SH-11037 (yellow) docks in the substrate-binding cleft of sEH, as shown in 
this stereo view. Key residues are shown in green. e) 2D interaction diagram for docked SH-
11037. The protein “pocket” is displayed with a line around the ligand, colored with the color of 
the nearest protein residue. The π-π stacking interactions are shown as green lines. 
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Figure 2. SH-11037 is an sEH inhibitor. a) SH-11037 (1) but not its inactive analog SH-11098 
(6) significantly suppressed sEH enzymatic activity in vitro, IC50 = 0.15 µM (SH-11098 IC50 > 10 
µM). The specific sEH inhibitors t-AUCB (5) and compound 7 were used as positive controls, 
IC50 = 9.5 nM for each. Mean ± SEM from triplicate wells shown. b) Michaelis-Menten kinetic 
response plot for sEH-mediated hydrolysis of fluorescent substrate, PHOME, for varying SH-
11037 concentrations. Mean ± SEM from triplicate wells shown. c) Lineweaver-Burk plot of 
these data suggests mixed-type inhibition. d) Dixon plot further supports mixed-type inhibition. 
e) Lipid profile of retina/choroid for DHA-related metabolites from L-CNV (three days post-
laser) or control mice treated with vehicle, 10 µM t-AUCB, or 10 µM SH-11037. EDP, 
epoxydocosapentaenoic acids; DHDP, dihydroxydocosapentaenoic acids. f) The ratio of 19,20 
EDP/DHDP between different treatment conditions and vehicle only (no laser) control mice 
indicates increased sEH levels/activity three days following laser induction compared to no 
laser control, **P<0.01, and a significant sEH inhibition by SH-11037, *P<0.05 vs. vehicle. 
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One-way ANOVA, Dunnett’s post hoc tests. Mean ± SEM, n = 5 mice/treatment. Activity assay 
and kinetic analyses are representatives from at least two independent experiments. 
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Figure 3. sEH is upregulated in the eyes of mice and humans undergoing neovascularization. 
a) Representative images of retinal sections from L-CNV and control eyes stained with DAPI 
(blue), agglutinin for vasculature (green), and sEH (magenta), showing upregulation of sEH in 
the outer retina in L-CNV sections three days post-laser. b) Immunoblot of sEH protein levels 
in mouse retina and choroid sections of laser treated mouse eyes three days post-laser 
compared to untreated controls; β-actin is a loading control. Pooled eyes from two 
independently-treated animals per condition. c) Representative images of retinal sections from 
L-CNV (three days post-laser) and control eyes stained with DAPI (blue), sEH (magenta), and 
rod marker rhodopsin (green), showing co-localization of upregulated sEH with rod 
photoreceptors. d) sEH activity is upregulated in L-CNV eye tissue (*P<0.05) and normalized 
by 20 µM SH-11037 or 7 treatment (***P<0.001), as indicated in a trans-stilbene oxide 
enzymatic activity assay performed three days post-laser. Mean ± SEM, ANOVA with Tukey’s 
post hoc tests. Pooled data from three experiments, n = 2–3 animals per condition per 
experiment. e) Representative images of central retinal sections from eyes of human wet AMD 
patients (78 years old) and age-matched controls (68 years old). sEH is magenta, vasculature 
(FITC-agglutinin) is green, and nuclei (DAPI) are blue. In wet AMD, sEH is increased in the 
inner retina, and aberrantly expressed in some photoreceptors (arrowheads). Scale bars = 50 
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µm. IgG is a negative control with preimmune primary antibodies. GCL, ganglion cell layer; 
INL, inner nuclear layer; ONL, outer nuclear layer; IS/OS, photoreceptor inner segments/outer 
segments; RPE, retinal pigment epithelium.  
Page 19 of 22
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 20 
Figure 4. Local application of sEH inhibitors dose-dependently suppresses neovascularization. 
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a) Representative images from confocal microscopy of agglutinin stained CNV lesions 14 days 
post-laser, scale bar = 50 µm. b) & c) Dose-dependent inhibition of the volume of CNV lesions 
by b) t-AUCB (6) and c) sEH inhibitor 7 compared to vehicle control. Mean ± SEM, n = 6–15 
animals/treatment (one eye per animal). *P<0.05, **P<0.01, ***P<0.001 compared to vehicle, 
one-way ANOVA, Dunnett’s post hoc tests. d) & e) Inhibition of mouse choroidal sprouting ex 
vivo by d) t-AUCB (6) and e) sEH inhibitor 7 compared to vehicle control. Mean ± SEM, n = 4 
eyes/treatment, representative data from at least two independent experiments. Axes for 
measurement of sprouting distance shown in yellow. Scale bars = 1 mm. *P<0.05, **P<0.01 
compared to vehicle, one-way ANOVA, Dunnett’s post hoc tests. f) Summary of SH-11037’s 
mechanism. By inhibiting sEH, SH-11037 decreases the formation of 19,20-DHDP 
(dihydroxydocosapentaenoic acid), and increases levels of docosahexaenoic acid (DHA)-
derived 19,20-EDP (epoxydocosapentaenoic acid), with antiangiogenic effects. 
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Supplementary Figure 1. Peptide mass fingerprinting analysis of proteins pulled down 
with an SH-11037 affinity reagent from a porcine brain lysate. EPHX2 was the top-
scoring protein hit not also seen in a size-matched control sample (shared hits are 
colored blue). 
  
Accession Description Score Coverage # Unique 
Peptides
# Peptides # PSMs MW [kDa]
P00761 Trypsin OS=Sus scrofa PE=1 SV=1 - [TRYP_PIG] 168.82 54.98 7 7 56 24.4
F1S0L1 Uncharacterized protein OS=Sus scrofa GN=LOC100737113 PE=3 SV=2 - [F1S0L1_PIG] 83.66 17.26 6 7 24 51.5
Q6Q2C2 Bifunctional epoxide hydrolase 2 OS=Sus scrofa GN=EPHX2 PE=2 SV=1 - [HYES_PIG] 73.43 29.91 12 12 18 62.7
F2Z571 Uncharacterized protein OS=Sus scrofa GN=LOC100516352 PE=2 SV=1 - [F2Z571_PIG] 53.69 17.98 2 6 15 49.8
P02554 Tubulin beta chain OS=Sus scrofa PE=1 SV=1 - [TBB_PIG] 52.07 17.98 2 6 14 49.8
I3LDS3 Uncharacterized protein OS=Sus scrofa GN=LOC100519971 PE=3 SV=1 - [I3LDS3_PIG] 43.13 9.60 5 6 14 58.0
F1SGG3 Uncharacterized protein OS=Sus scrofa GN=KRT1 PE=3 SV=1 - [F1SGG3_PIG] 40.91 7.31 2 5 19 65.2
F2Z5T5 Tubulin alpha-1B chain OS=Sus scrofa GN=TUBA1B PE=3 SV=1 - [F2Z5T5_PIG] 39.96 25.06 1 7 11 50.1
F1SHC1 Uncharacterized protein OS=Sus scrofa GN=LOC100127131 PE=3 SV=1 - [F1SHC1_PIG] 38.21 25.17 1 7 10 49.9
I3LNT6 Uncharacterized protein OS=Sus scrofa GN=KRT77 PE=3 SV=1 - [I3LNT6_PIG] 37.49 5.34 1 3 19 62.3
I3LDM6 Uncharacterized protein OS=Sus scrofa GN=LOC100157304 PE=3 SV=1 - [I3LDM6_PIG] 31.25 8.24 3 6 10 65.1
F1SGG6 Uncharacterized protein (Fragment) OS=Sus scrofa GN=KRT5 PE=3 SV=2 - [F1SGG6_PIG] 23.32 10.25 4 6 8 63.4
F1SGG4 Uncharacterized protein OS=Sus scrofa PE=3 SV=2 - [F1SGG4_PIG] 21.37 8.45 1 4 7 53.3
F1SGI7 Uncharacterized protein (Fragment) OS=Sus scrofa GN=LOC100525745 PE=3 SV=2 - [F1SGI7_PIG] 17.16 6.89 2 4 6 65.1
F1RUN2 Serum albumin OS=Sus scrofa GN=ALB PE=4 SV=1 - [F1RUN2_PIG] 11.08 2.14 1 1 3 69.6
 4 
Supplementary Figure 2. Molecular dynamics simulation results. (a) Root-mean-
squared deviation (RMSD) of SH-11037 (ligand; black) and sEH (receptor; red) over the 
course of several nanoseconds of molecular dynamics simulations; see Supplementary 
Movie. (b) Free energy parameters calculated by MMPBSA, computed means ± SEM; 
see Experimental Procedures. 
  
∆EVDW ∆EELE ∆EGB ∆ESURF ∆EGBTOT T∆SNMODE ∆GMMGBSA
Energy 
(kcal/mol) -83.6±0.2 -30.5±0.2 57.9±1.1 -10.7±0.0 -66.9±0.2 -22.7±1.4 -44.1±0.2
a
b
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Supplementary Figure 3. Kinetic analysis for sEH inhibition by compound 7. (a) 
Michaelis-Menten kinetic response plot for hydrolysis of fluorescent substrate, PHOME. 
(b) Lineweaver-Burk plot indicates mixed-type inhibition. (c) Ki = 19.6 ± 5.4 nM is 
illustrated on Dixon plot. Mean ± SEM, n = 3. Representative results from at least two 
independent experiments. 
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Supplementary Figure 4. Secondary plots for enzyme kinetic analyses. The apparent 
KM/Vmax data fit the expected profiles for mixed-type inhibition by SH-11037 and 7. (a) 
KMapp/Vmaxapp and 1/Vmaxapp vs. [SH-11037]. (b) KMapp/Vmaxapp and 1/Vmaxapp vs. [7]. 
Representative results from at least two independent experiments. 
  
 7 
Supplementary Figure 5. Further evidence of sEH upregulation within L-CNV lesions 3 
days post-laser-treatment, and co-staining with rod (rhodopsin) but not cone (arrestin) 
markers. sEH is magenta, cell type markers are green, and nuclei (DAPI) are blue. 
GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; IS/OS, 
photoreceptor inner segments/outer segments; RPE, retinal pigment epithelium. Scale 
bars = 50 µm.  
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Supplementary Figure 6. sEH does not colocalize with markers of (a) horizontal cells 
(calbindin) or (b) retinal ganglion cells (Brn3a) in untreated C57BL/6 adult mouse eyes 
or in L-CNV eyes 3 days post-laser-treatment. sEH is magenta, cell type markers are 
green, and nuclei (DAPI) are blue. GCL, ganglion cell layer; INL, inner nuclear layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner segments/outer segments; RPE, 
retinal pigment epithelium. Scale bars = 50 µm. 
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Supplementary Figure 7. sEH does not colocalize with markers of (a) cone 
photoreceptors (cone arrestin) or (b) Müller glia (vimentin) in untreated C57BL/6 adult 
mouse eyes or in L-CNV eyes, 3 days post-laser-treatment. Inset shows magnification 
of area marked by dotted lines. sEH is magenta, cell type markers are green, and nuclei 
(DAPI) are blue. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear 
layer; IS/OS, photoreceptor inner segments/outer segments; RPE, retinal pigment 
epithelium. Scale bars = 50 µm. 
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Supplementary Figure 8. Validation of sEH antibodies. A5 (magenta) is a mouse 
monoclonal antibody against sEH, while H215 (green) is a rabbit polyclonal antibody 
against sEH. Both antibodies show a similar staining pattern in murine retina, indicative 
of specificity for the target protein. GCL, ganglion cell layer; INL, inner nuclear layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner segments/outer segments; RPE, 
retinal pigment epithelium. Scale bars = 50 µm. 
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Supplementary Figure 9. Further example of differential sEH staining in the central 
retina of human wet AMD eyes (68 years old) versus age-matched controls (78 years 
old). sEH is magenta, vasculature (FITC-agglutinin) is green, and nuclei (DAPI) are 
blue. In wet AMD, sEH is increased in the inner retina, and aberrantly expressed in 
some photoreceptors (arrowheads). GCL, ganglion cell layer; INL, inner nuclear layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner segments/outer segments; RPE, 
retinal pigment epithelium. Scale bars = 50 µm. 
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EXPERIMENTAL PROCEDURES 
Preparation of Photoaffinity Reagents. Photoaffinity reagents were synthesized as 
described,1 with purity confirmed as >95% by HPLC. For pulldowns, Neutravidin 
agarose beads (1 mL of 50% (v/v) slurry) were washed three times in buffer A (25 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 2.5 mM sodium pyrophosphate, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 0.1 mM sodium orthovanadate, 10 µg/mL 
aprotinin and 10 µg/mL leupeptin). The beads were then incubated with 75 µM affinity 
reagents 2, 3, or 4 dissolved in DMSO (final DMSO concentration <0.1% (v/v)) and 
diluted in this buffer, overnight at 4°C with rotation. The beads were blocked using 1 mM 
biotin solution prepared in buffer A for 1 hour followed by incubation with 1 mg/mL 
cytochrome c solution for 1 hour at 4°C. The beads were then washed three times with 
buffer A and resuspended in 1 mL. 
 
Photoaffinity Pulldown Experiments. Flash-frozen porcine brain (20 g) obtained from 
the Purdue-Indiana University School of Medicine Comparative Medicine Program was 
homogenized in 50 mL buffer A using a tissue homogenizer. The homogenate was 
centrifuged and sonicated. The lysate was then centrifuged at 11,000×g for 30 min. The 
resulting supernatant (S2) was collected. The pellet (P1) was resuspended in buffer A 
and centrifuged at 11,000×g for 30 min; supernatant (S3) was collected. Both S2 and 
S3 supernatants were divided equally and each fraction was incubated with 500 µL 
photoaffinity or control reagent conjugated to Neutravidin beads for 75 min at 4°C with 
shaking. The beads were collected by centrifugation then resuspended in buffer A + 1% 
(v/v) Triton X-100 and irradiated with 365 nm UV light (Mercury bulb H44GS100 from 
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Sylvania in a Blak-Ray 100A long-wave UV lamp with output of 25 mW/cm2 at sample 
distance) for 30 min at 4°C. The beads were then washed in high-salt buffer containing 
25 mM Tris-HCl pH 7.4, 350 mM NaCl, 1% (v/v) Triton X-100 and 1 mM PMSF. The 
beads were washed again in salt-free buffer containing 25 mM Tris-HCl, 1% (v/v) Triton 
X-100 and 1 mM PMSF. After 5 min incubation, the beads were collected, then boiled in 
SDS-PAGE gel loading dye containing 2-mercaptoethanol for 10 min at 70°C to release 
the bound proteins. After boiling, the contents were allowed to cool and after a quick 
spin the eluate was collected using a Hamilton syringe. The eluates were then analyzed 
in 4–20% (w/v) gradient SDS-PAGE and the protein bands were visualized using silver 
staining.2 The protein bands pulled down specifically by photo-affinity reagent were 
excised from the silver stained SDS-PAGE gel and analyzed by mass spectrometry 
(IUSM Proteomics Core). Using SequestTM algorithms and the swine database 
(UniProt), the identities of the pulled down proteins were confirmed (Supplementary 
Figure 1). 
 
Immunoblot Assay. Cell lysates were prepared by homogenizing retina and choroid in 
NP-40 lysis buffer (25 mM HEPES pH 7.6, 150 mM NaCl, 1% (v/v) NP-40, 10% (v/v) 
glycerol, 1 mM sodium orthovanadate, 10 mM NaF, 1 mM PMSF, 10 µg/mL aprotinin, 1 
µM pepstatin, 1 µM leupeptin) and then centrifuged at 12,000×g for 15 min at 4°C. 
Supernatant was collected and protein concentration was determined using a Bradford 
assay. Equal amounts of total protein (40 µg) from each sample were resolved by 10% 
(w/v) SDS-PAGE and then transferred onto PVDF membranes. Proteins were 
immunoblotted with antibodies against sEH (H215) (Santa Cruz) at 1:1000 dilution, and 
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b-actin (AC40) (Sigma-Aldrich) at 1:5000. Secondary antibodies (Thermo Fisher 
Scientific) were used at 1:10,000 dilutions. All of the dilutions were made in Tris 
Buffered Saline-0.05% (v/v) Tween-20 buffer containing 2% (w/v) bovine serum albumin 
(BSA). Signals were detected using Amersham ECL immunoblotting detection reagents 
on a Typhoon molecular imager (GE Healthcare). 
 
Protein Structure Preparation for Molecular Dynamics. A crystal structure of sEH 
(PDB ID: 3I283) was retrieved and prepared using the Protein Preparation Wizard in the 
Schrödinger software package (Schrödinger LLC).4, 5 Bond orders were assigned and 
hydrogen atoms were added. Missing side chains and loops were introduced using the 
Prime module.6 The resulting protein structure was protonated at pH 7.0 using 
PROPKA.7 
 
Ligand Preparation for Docking. Compound SH-11037 was prepared using LigPrep.4 
Epik was used for protonation-state assignment and tautomer generation.8 The 
OPLS_2005 force field was used for minimization and ionization states were generated 
at pH 7.9 Compound was desalted to exclude additional molecules such as counter ions 
in salt and water molecules and tautomers were generated. All possible stereoisomer 
states were generated for a given compound, up to 32 different states per ligand. 
 
Docking. Molecular docking was performed by Glide in standard-precision (SP) 
model.10-12 The grids for docking were generated using the receptor grid generation tool 
in Maestro using an inner box of size 14 Å ×14 Å ×14 Å with dock ligands less than or 
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equal to 21 Å, and other settings left at the default. The docking mode of benzene ring 
exposed was selected for the final structure, as the para position of the benzene 
provides the probability of attachment of the linker. 
 
Molecular Dynamics Simulations. The final docking model was used to run molecular 
dynamics simulations using the AMBER14 software package.13 The compound was 
assigned AM1-BCC14 charges and gaff15 atom types using antechamber.16 Crystal 
water molecules were retained. Complexes were immersed in a box of TIP3P water 
molecules.17 No atom on the complex was within 14 Å from any side of the box. The 
solvated box was further neutralized with Na+ or Cl- counterions using the tleap 
program. Simulations were carried out using the GPU accelerated version of the 
pmemd program with ff14SB18 and gaff force fields15 in periodic boundary conditions. All 
bonds involving hydrogen atoms were constrained by using the SHAKE algorithm19, and 
a 2 femtosecond (fs) time step was used in the simulation. The particle mesh Ewald 
(PME) method20 was used to treat long-range electrostatics. Simulations were run at 
298 K under 1 atm in NPT ensemble employing Langevin thermostat and Berendsen 
barostat. Water molecules were first energy-minimized and equilibrated by running a 
short simulation with the complex fixed using Cartesian restraints. This was followed by 
a series of energy minimizations in which the Cartesian restraints were gradually 
relaxed from 500 kcal∙Å–2 to 0 kcal∙Å–2, and the system was subsequently gradually 
heated to 298 K with a 48 ps molecular dynamics run. For each complex, we generated 
10 independent simulations (replicates) that are each 10 ns in length. The initial velocity 
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of each replicate was randomly assigned. In total, 100 ns of simulation was run for each 
complex.  
 
MMGBSA Free Energy Calculations. In the 10 trajectories (10 ns in length), the first 2 
ns were discarded for equilibration. Snapshots were saved every 1 ps, yielding 8000 
structures per trajectory. A total of 80000 snapshots were generated in 100 ns of 
simulation. 1000 snapshots were selected at regular intervals from the 80000 snapshots 
for free energy calculations using the cpptraj program.21 The Molecular Mechanics-
Generalized Born Surface Area (MM-GBSA)22 method was used to calculate the free 
energy using the MMPBSA.py script.23 The calculation using the GB method was 
performed with sander and Onufriev’s GB model.24, 25 Solvent-accessible surface area 
(SASA) calculations were switched to the icosahedron (ICOSA) method, where surface 
areas are computed by recursively approximating a sphere around an atom, starting 
from an icosahedron. Salt concentration was set to 0.1 M. The entropy was determined 
by normal mode calculations 26 with the mmpbsa_py_nabnmode module by selecting 50 
of the 1000 snapshots used in the free energy calculations at regular intervals. The 
maximum number of cycles of minimization was set to 10000. The convergence 
criterion for the energy gradient to stop minimization was 0.5. In total, 1000 frames were 
used for each MM-GBSA calculation while 50 frames were used for each normal mode 
analysis. All other parameters were left at default values. 
The MM-GBSA binding free energy is expressed as: 
∆GMM-GBSA = ∆EGBTOT − T∆SNMODE 
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where ∆EGBTOT is the combined internal and solvation energies, T is the temperature 
(298.15 K), and ∆SNMODE is the entropy determined by normal mode calculations. The 
total enthalpy from the generalized Born model, ∆EGBTOT, is the sum of 4 components: 
∆EGBTOT = ∆EVDW + ∆EELE + ∆EGB + ∆ESURF 
where ∆EVDW and ∆EELE are the van der Waals and electrostatic energies, respectively, 
and ∆EGB and ∆ESURF are the polar and non-polar desolvation energies, respectively. All 
binding energies are determined by: 
∆E = ECOM – EREC – ELIG 
where ECOM, EREC and ELIG are total energies corresponding to the complex, receptor, 
and ligand, respectively. 
 
Recombinant Soluble Epoxide Hydrolase Activity Assay. Small molecule inhibition 
of soluble epoxide hydrolase (sEH) enzymatic activity was evaluated using the sEH 
inhibitor screening assay kit based on the synthetic, fluorogenic substrate PHOME (3-
phenyl-cyano(6-methoxy-2-naphthalenyl)methyl ester-2-oxiraneacetic acid) (Cayman 
Chemical) following manufacturer’s instructions, using varying concentrations of SH-
11037 (1) (synthesized as described27), t-AUCB (5) (Cayman Chemical), and 6 
(synthesized as described27). Benzisoxazole sEH inhibitor 7 was synthesized according 
to a published method, and characterization matched published parameters.28 Purity of 
all synthesized compounds was >95% by HPLC. Compounds were dissolved in DMSO 
(final DMSO concentration = 5% (v/v)).  Activity was calculated according to: 
% Initial Activity = [(FI15 – FI0)/(FT15 – FT0)] x 100% 
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Where FI is the background corrected fluorescence signal obtained in the presence of 
an inhibitor and FT is the background corrected fluorescence signal obtained for the total 
activity at times 0 and 15 minutes. IC50 values were calculated using GraphPad Prism v. 
7.0.  
 
sEH Enzyme Kinetics. Various concentrations of compound dissolved in DMSO (final 
DMSO concentration = 5% (v/v)) and human sEH (60 ng/mL final concentration; 
Cayman Chemical) in 25 mM bis-Tris-HCl buffer containing 0.1% (w/v) BSA were mixed 
in a 96 well plate. PHOME at indicated concentrations was added to the wells to initiate 
the reaction and fluorescence was read with an excitation wavelength of 330 nm and 
emission wavelength of 465 nm. The standard curve plotted from dilutions of the 
product, 6-methoxy-2-naphthaldehyde, was used to convert fluorescence reading 
(RFU/min) to sEH activity (nmol product formed/min). The reaction rate was obtained 
from the slope of the line from time = 5 to 15 minutes for each substrate concentration, 
and analyzed using GraphPad Prism 7 and SigmaPlot 13.0 to determine Michaelis-
Menten kinetic parameters. 
 
Mice. All mouse experiments followed the guidelines of the Association for Research in 
Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual 
Research and were approved by the Indiana University School of Medicine Institutional 
Animal Care and Use Committee. Wild-type female C57BL/6J mice, 6–8 weeks of age, 
were purchased from the Jackson Laboratory. Intraperitoneal injections of 17.5 mg/kg 
ketamine hydrochloride and 2.5 mg/kg xylazine mixture were used for anesthesia. At 
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the end of the experiments, mice were euthanized by carbon dioxide asphyxiation 
followed by cervical dislocation. 
 
Laser-induced Choroidal Neovascularization. The L-CNV mouse model and 
injections were performed as previously described.29 Briefly, eyes were dilated using 1% 
(w/v) tropicamide, then underwent laser treatment using 50 µm spot size, 50 ms 
duration, and 250 mW pulses of an ophthalmic argon green laser, wavelength 532 nm, 
coupled to a slit lamp. Compounds where indicated were injected a single time 
immediately post-laser treatment, delivered intravitreally using a 33-gauge needle, in a 
0.5 µL volume. SH-11037, t-AUCB, or 7 were dissolved in DMSO then diluted in PBS to 
a final concentration of 0.5% (v/v) DMSO. Vehicle alone (PBS + 0.5% (v/v) DMSO) was 
used as negative control. Mouse anti-VEGF164 antibody (AF-493-NA, R&D Systems) at 
a 5 ng dose was used as a positive control for inhibition of neovascularization. Eyes 
were numbed with tetracaine solution before the injection, and triple antibiotic ointment 
was used immediately after the injection to prevent infection. 
 
Lipid Profiling. C57BL/6J mice underwent laser treatment followed by intravitreal 
injections of 10 µM SH-11037, 10 µM t-AUCB or vehicle control as described above. 
Mice were sacrificed 3 days post-laser-treatment, eyes were enucleated and 
retina/choroid layers were immediately separated and stored at –80°C. Lipid profile 
analysis was performed by the Lipidomics Core Facility at Wayne State University using 
standard operating procedures developed by the core as previously described.30  
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Immunohistochemistry. Eyes from L-CNV and control mice fixed in 4% (w/v) PFA 
overnight were paraffin embedded and sectioned. Human donor eyes from wet AMD 
patients or age-matched controls with no documented ocular pathology were obtained 
from the National Disease Research Interchange (NDRI; Philadelphia, PA) with full 
ethical approval for use in research. All sample tissues were anonymized prior to receipt 
in the laboratory. Eye sections were deparaffinized, rehydrated and underwent heat 
induced antigen retrieval. Sections were washed in TBS and blocked in 10% (v/v) 
DAKO diluent in TBST/1% (w/v) BSA for an hour at room temperature, then incubated 
with primary antibodies overnight at 4°C. Primary antibodies and dilutions used were 
rabbit anti-sEH, H215 (1:250 for mouse, 1:90 for human; Santa Cruz); mouse anti-sEH, 
A5 (1:250; Santa Cruz); Ricinus communis agglutinin I (rhodamine labeled, 1:250 for 
mouse; FITC-labeled, 1:400 for human; Vector Labs); mouse anti-rhodopsin, ab3424 
(1:300; Abcam); rabbit anti-cone arrestin, AB15282 (1:500; Millipore); mouse-anti-
calbindin, ab11426 (1:300, Abcam); rabbit anti-Brn3a, AB5945 (1:400; Millipore); and 
rabbit anti-vimentin PLA0199 (1:300; Sigma) diluted in 10% (v/v) DAKO diluent in 
TBST/1% (w/v) BSA (only PBS/1% (w/v) BSA for human). Sections were then incubated 
with secondary antibodies, Alexa Fluor 488 (647 for human) goat anti-rabbit and Alexa 
Fluor 555 goat anti-mouse (Abcam) diluted 1:400 (1:500 for human) in 10% (v/v) DAKO 
diluent in TBST/1% (w/v) BSA (only PBS/1% (w/v) BSA for human) for 45–60 minutes at 
room temperature, followed by a brief wash in TBS, dehydration through an ethanol 
series and mounting with Vectashield mounting medium with DAPI (Vector Labs). 
Images were acquired with an LSM700 confocal microscope (Zeiss) with a 20x 
objective or, for human sections, an AxioImager D2 (Zeiss). 
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Tissue-based sEH Activity Assay using trans-Stilbene Oxide. The sEH activity in 
tissue homogenates was assayed using trans-stilbene oxide (t-SO) as substrate. The 
assay is based on the hydrolysis of t-SO that is tracked as a decrease in the 
absorbance at 230 nm.31, 32 L-CNV was induced as described above. After 3 days, 
enucleated eyes from both untreated and L-CNV mice were homogenized in 0.2 M 
sodium phosphate buffer, pH 7.4. In order to remove microsomal epoxide hydrolase and 
lenses, tissue extracts were centrifuged at 100,000×g for 30 minutes at 4°C. After 
protein estimation, 100 µL of tissue homogenates (100 µg/mL) and 98 µL of SH-11037 
or 7 dissolved in DMSO/buffer (final 1% (v/v) DMSO) were added to a UV-transparent 
96-well plate. After 5 minutes’ incubation at room temperature, 2 µL of t-SO in ethanol 
(100 µM final concentration) was added to assay wells to initiate the reaction. The 
absorbance was read at 230 nm for 20 minutes. sEH activity was determined as follows: 
sEH Activity  =  [(A0 –  A20) – (B0 – B20)]/mg of protein in a reaction 
Where A0 and A20 are absorbance of test wells read at 230 nm at time 0 and 20 minutes 
respectively, and B0 and B20 are absorbance of background wells read at 230nm at time 
0 and 20 minutes. 
 
Choroidal Flatmount and Analysis. To assess neovascularization in response to 
treatments, 14 days post-L-CNV induction, eyes were enucleated, fixed and stained as 
described.33 Choroid/sclera layers were incubated with rhodamine labeled Ricinus 
communis agglutinin I (Vector Labs), in the dark for 45 minutes, to stain blood vessels. 
Flatmounts of the choroid were mounted with Vectashield mounting medium (Vector 
 22 
Labs) and Z-stack images were taken on an LSM700 confocal microscope (Zeiss). 
ImageJ software was used to analyze Z-stack images. This experiment was performed 
by a masked investigator and followed the guidelines and exclusion criteria described 
previously,34 to ensure reproducibility and eliminate investigator bias.  
 
Choroidal Sprouting Assay. Sprouting of endothelial cells from choroidal layers was 
tested as previously described.33 t-AUCB or 7 dissolved in DMSO was tested at 0.1, 1, 
and 10 µM concentrations for 48 hours. The final concentration of DMSO in each well 
was 0.2% (v/v). Images were taken using an EVOS-fl digital microscope (AMG) and 
data were analyzed as the sprouting distance in four different directions using ImageJ 
software v.1.48v (http://imagej.nih.gov/ij/). 
 
Statistical Analyses. Statistical analyses were performed with GraphPad Prism 7 
software. One-way ANOVA was used with Tukey’s post hoc test for lipid profiling and 
sEH analysis in tissue, and Dunnett’s post hoc test for L-CNV confocal analysis and 
choroidal sprouting experiments. Two-sided P values < 0.05 were considered 
statistically significant. 
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